Mandy Lauw: Can Reduced-Dose DOACs Be Applied to All Patients With VTE?
Mandy Lauw, Internist-hematologist at Erasmus MC, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“Evidence for the efficacy and safety of doac dose-reduction for extended VTE treatment is substantial with the renove, eve and api-cat trials. But does this apply to all patients?
This short narrative review in HemaSphere Journal, written together with Marc Carrier and Saskia Middeldorp, provides some relevant insights for clinicians whether reduced-dose doacs can be uniformly applied to all patients with thrombosis and an indication for long-term anticoagulation.”
Title: Extended treatment for venous thromboembolism: Is direct oral anticoagulant dose-reduction better for all?
Authors: Mandy N. Lauw, Saskia Middeldorp, Marc Carrier
Read the Full Article on HemaSphere Journal
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 29, 2026, 17:25Robert Brodsky: Ravulizumab Appears To Be Safe And Effective In Pregnancy
-
Apr 29, 2026, 16:53Chokri Ben Lamine: IV Iron Showdown – FCM vs Ferric Derisomaltose vs Iron Dextran
-
Apr 29, 2026, 16:46Deep Vein Thrombosis Risk in Jobs with Prolonged Sitting – NBCA
-
Apr 29, 2026, 16:41Vikramaditya Gangakar: Essential Pharmacy Facts You Should Know About Aspirin
-
Apr 29, 2026, 16:17W. Alberto Sifuentes Giraldo: Non-Criteria Manifestations of Antiphospholipid Syndrome
-
Apr 29, 2026, 16:12Mavis Agnes Kisakye: Concluding a Successful Entrepreneurs Training for Empowering Ptients’ Mothers
-
Apr 29, 2026, 15:48Kriti Batni: Happy to Share Current Use and Future Directions of Monoclonal Antibodies in Medicine Update 2026
-
Apr 29, 2026, 15:46Dima Shulkin: Comparing HALP and PIV for Mortality Prediction in ACS
-
Apr 29, 2026, 15:44Sonal Sonu: Securing First Prize in Research Oral Presentation at the CME